On Friday, Biogen Inc (NASDAQ: BIIB) was 1.71% up from the session before settling in for the closing price of $164.73. A 52-week range for BIIB has been $110.04 – $175.86.
Annual sales at Healthcare sector company slipped by -18.66% over the past five years. When this article was written, the company’s average yearly earnings per share was at -9.03%. With a float of $146.43 million, this company’s outstanding shares have now reached $146.70 million.
Biogen Inc (BIIB) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Biogen Inc stocks. The insider ownership of Biogen Inc is 0.19%, while institutional ownership is 91.30%. The most recent insider transaction that took place on Sep 02 ’25, was worth 69,045. In this transaction Head of Development of this company sold 517 shares at a rate of $133.55, taking the stock ownership to the 5,772 shares. Before that another transaction happened on Sep 02 ’25, when Company’s Officer proposed sale 517 for $133.55, making the entire transaction worth $69,045.
Biogen Inc (BIIB) Latest Financial update
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted 3.44 earnings per share (EPS) during the time that was better than consensus figure (set at 3.36) by 0.08. Wall Street market experts anticipate that the next fiscal year will bring earnings of 3.49 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -9.03% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.54% during the next five years compared to -18.66% drop over the previous five years of trading.
Biogen Inc (NASDAQ: BIIB) Trading Performance Indicators
You can see what Biogen Inc (BIIB) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 2.04. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.54. Likewise, its price to free cash flow for the trailing twelve months is 10.67.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 10.97, a number that is poised to hit 1.80 in the next quarter and is forecasted to reach 15.20 in one year’s time.
Technical Analysis of Biogen Inc (BIIB)
Biogen Inc (NASDAQ: BIIB) saw its 5-day average volume 2.01 million, a positive change from its year-to-date volume of 1.6 million. As of the previous 9 days, the stock’s Stochastic %D was 89.99%.
During the past 100 days, Biogen Inc’s (BIIB) raw stochastic average was set at 96.98%, which indicates a significant increase from 95.32% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 5.62 in the past 14 days, which was higher than the 4.28 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $148.37, while its 200-day Moving Average is $135.90. Nevertheless, the first resistance level for the watch stands at $170.03 in the near term. At $172.52, the stock is likely to face the second major resistance level. The third major resistance level sits at $176.03. If the price goes on to break the first support level at $164.03, it is likely to go to the next support level at $160.52. The third support level lies at $158.03 if the price breaches the second support level.
Biogen Inc (NASDAQ: BIIB) Key Stats
There are 146,702K outstanding shares of the company, which has a market capitalization of 24.58 billion. As of now, sales total 9,676 M while income totals 1,632 M. Its latest quarter income was 2,535 M while its last quarter net income were 466,500 K.
